Search - tctmd.com

Displaying 821 - 840 of 1957

Sort: Relevancy | Date

Presentation TCT 2016

My Most Challenging Case 2016: STEMI with Multivessel Disease

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Ning Guo

October 31, 2016

Presentation TCT 2016

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Presenter: Neil E. Moat, John G. Webb, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

Presenter: Neil E. Moat, John G. Webb, Ian T. Meredith

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe LV Dysfunction

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Qi Zhang

October 31, 2016

Presentation TCT 2016

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Presenter: Neil E. Moat, John G. Webb, Marina Urena

October 31, 2016

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

Presenter: Neil E. Moat, John G. Webb, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Chronic Total Occlusion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Bin Zhang

October 31, 2016

Presentation TCT 2016

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

Presenter: Neil E. Moat, John G. Webb, Alexandra J. Lansky

October 31, 2016

Presentation TCT 2016

ACT I Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Klaus D. Mathias

October 31, 2016

Presentation TCT 2016

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

Presenter: William A. Gray, Stephan Windecker, Kenneth Rosenfield

October 31, 2016

Presentation TCT 2016

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

Presenter: Neil E. Moat, John G. Webb, Adam B. Greenbaum

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe Calcified Lesion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Juying Qian

October 31, 2016

Presentation TCT 2016

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

Presenter: Neil E. Moat, John G. Webb, Stephen R. Ramee

October 31, 2016

Presentation TCT 2016

CTSN Severe MR 2-Year Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Patrick M. McCarthy

October 31, 2016

Presentation TCT 2016

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Presenter: Neil E. Moat, John G. Webb, Pieter R. Stella

October 31, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation TCT 2016

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Presenter: Neil E. Moat, John G. Webb, Eric Van Belle

October 31, 2016

Presentation TCT 2016

EFS in the USA: Challenges and Developments (An Investigators Perspective)

Presenter: Andrew Farb, Aaron V. Kaplan, Martin B. Leon

October 31, 2016

Presentation TCT 2016

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Presenter: Neil E. Moat, John G. Webb, Scott Lim

October 31, 2016

Advertisement

My Most Challenging Case 2016: STEMI with Multivessel Disease

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

My Most Challenging Case 2016: Severe LV Dysfunction

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

My Most Challenging Case 2016: Chronic Total Occlusion

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

ACT I Critique: Pro and Con

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

My Most Challenging Case 2016: Severe Calcified Lesion

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

CTSN Severe MR 2-Year Critique: Pro and Con

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

EFS in the USA: Challenges and Developments (An Investigators Perspective)

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content